Tevogen Bio Holdings (TVGN) Cash from Operations (2022 - 2026)

Tevogen Bio Holdings has reported Cash from Operations for 5 years, with the latest figure at 2733769.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 17.36% year-over-year to 2733769.0; the trailing twelve-month figure through Mar 2026 stood at 11754283.0 (up 10.57% YoY), and the FY2025 full-year result was 12328577.0, down 2.75% from the prior year.
• Cash from Operations for Q1 2026 stood at 2733769.0, down from 2181267.0 in the prior quarter.
• The five-year high for Cash from Operations was 13861.0 in Q4 2022, with the low at 3804709.0 in Q3 2024.
• Historically, Cash from Operations has averaged 2085152.29 across 5 years, with a median of 2181267.0 in 2025.
• Annual changes were most pronounced in 2023 — Cash from Operations plunged 14159.23% — and 2025, when it advanced 28.43%.
• Tevogen Bio Holdings' Cash from Operations stood at 13861.0 in 2022, then sank by 14159.23% to 1976472.0 in 2023, then plunged by 54.2% to 3047686.0 in 2024, then gained by 28.43% to 2181267.0 in 2025, then retreated by 25.33% to 2733769.0 in 2026.
• The last three Cash from Operations figures came in at 2733769.0 (Q1 2026), 2181267.0 (Q4 2025), and 3649544.0 (Q3 2025), per Business Quant data.